Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Amazon

MercadoLibre

All three of these stocks have impressive growth prospects.

A New Bull Market Is in Sight: 3 Stocks to Buy Sooner Rather Than Later

Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

Teva filed an ANDA challenge against Auvelity four months after approval. The filing defines, for me, the hurdles generics will face in challenging Axsome's huge patent estate.

Axsome: Teva's ANDA Is No Surprise And No Big Deal

Axsome Therapeutics (NASDAQ: AXSM ) stock is taking a beating on Monday as rival Teva Pharmaceutical (NYSE: TEVA ) prepares a generic depression drug. According to a filing with the U.S. Securities and Exchange Commission (SEC), Teva Pharmaceutical intends to make its own generic version of Auvelity.

Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug

Teva Pharmaceutical

Teva Pharmaceutical said Monday it plans to make a knockoff of Axsome Therapeutics' new depression treatment, leading AXSM stock to tumble. The post Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling appeared first on Investor's Business Daily.

Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling

Shares of Axsome Therapeutics Inc. AXSM, -0.27% tumbled about 10.0% in premarket trading on Monday after the company said in a securities filing that Teva Pharmaceutical Industries Ltd. TEVA, +4.48% is seeking approval from the Food and Drug Administration to market a generic version of Auvelity, Axsome's depression treatment.

Axsome's stock falls after disclosing Teva's plans to market generic Auvelity

Eli Lilly

Vertex Pharmaceuticals

Maybe there's no such thing as a sure thing. But these stocks could come close.

3 Surefire Growth Stocks You Can Buy Right Now

Occidental Petroleum

These stocks could enjoy their own bull markets regardless of what the overall market does.

3 Stocks That Could Soar Whether There's a New Bull Market or Not

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, Feb. 15, 2023, at 8:40 a.m. Eastern Time.

Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference

Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27

Albemarle

Inspire Medical Systems Inc

These three companies should deliver inflation-busting long-term growth.

The Ultimate Growth Stocks to Buy With $300 Right Now

Inmode Ltd

2 Promising New Growth Stocks to Watch in 2023

AbbVie

These companies have what it takes to drive long-term share performance.

3 Unstoppable Stocks to Keep Buying in 2023

bluebird bio

These biotechs could crush the market, but there is more to the story.

2 Stocks That Could Double Your Money in 2023

Jazz Pharmaceuticals

These stocks look cheap if you take a long-term view.

These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.

Disney

Home Depot

Johnson & Johnson

NIKE

This may be the easiest of your New Year's resolutions. And it could pay off big.

5 Top Stocks to Buy to Start the New Year Right

Axsome has one pending approval and two pending NDAs coming up in 2023. They are adequately funded, if not very strongly.

Axsome: A Lot More Upside In 2023

Amylyx Pharmaceuticals

Alpha Metallurgical Resources

CONSOL Energy

Crescent Point Energy

Digi

Enphase Energy

First Solar

Golar LNG

International Seaways

Kellogg

Super Micro Computer

Semtech

Scorpio Tankers

Sierra Wireless

Transmedics Group Inc

Historic 2022 inflation lifted energy and value stocks while sinking growth plays. The post 100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles

Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well.

Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout

Novavax

These biotechs are far from having achieved their full potential.

2 Growth Stocks to Buy Heading Into 2023

Shopify

These businesses are growing and can be excellent places to make a sizable investment right now.

Got $5,000? 2 Unstoppable Stocks to Buy and Hold

Moderna

Revenue prospects look promising for both of these biotech companies.

Better Buy: Moderna vs Axsome

Arvinas Inc

Denali Therapeutics

Fate Therapeutics

Chart Industries

Karuna Therapeutics Inc

Rocket Pharma

Analysts say a tough 2022 has left these small-cap stocks priced for outperformance in the new year and beyond.

7 Best Small-Cap Stocks to Buy for 2022 and Beyond

Altimmune

Ardelyx

ProShares Ultra Nasdaq Biotechnology

Krystal Biotech

SPDR S&P Biotech ETF

Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond

Walmart

Stocks usually go down during recessions, but long-term investors can still come out on top.

Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows.

News for Axsome Therapeutics Stock (AXSM)